The Impact of Preoperative Breast MRI on Surgical Margin Status in Breast Cancer Patients Recalled at Biennial Screening Mammography: An Observational Cohort Study

Jessie J. J. Gommers, MSc¹, Lucien E. M. Duijm, MD, PhD², Peter Bult, MD, PhD³, Luc J. A. Strobbe, MD, PhD⁴, Toon P. Kuipers, MD⁵, Marianne J. H. Hooijen, MD⁶, Ritse M. Mann, MD, PhD¹,⁷, and Adri C. Voogd, PhD⁸

¹Department of Medical Imaging, Radboud University Medical Center, Nijmegen, The Netherlands; ²Department of Radiology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands; ³Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands; ⁴Department of Surgical Oncology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands; ⁵Department of Radiology, Bernhoven Hospital, Uden, The Netherlands; ⁶Department of Radiology, St Anna Hospital, Geldrop, The Netherlands; ⁷Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; ⁸Department of Epidemiology, Maastricht University, Maastricht, The Netherlands

ABSTRACT

Background. This study aimed to examine the association between preoperative magnetic resonance imaging (MRI) and surgical margin involvement, as well as to determine the factors associated with positive resection margins in screen-detected breast cancer patients undergoing breast-conserving surgery (BCS).

Methods. Breast cancer patients eligible for BCS and diagnosed after biennial screening mammography in the south of The Netherlands (2008–2017) were retrospectively included. Missing values were imputed and multivariable regression analyses were performed to analyze whether preoperative MRI was related to margin involvement after BCS, as well as to examine what factors were associated with positive resection margins, defined as more than focally (>4 mm) involved.

Results. Overall, 2,483 patients with invasive breast cancer were enrolled, of whom 123 (5.0%) had more than focally involved resection margins. In multivariable regression analyses, preoperative MRI was associated with a reduced risk of positive resection margins after BCS (adjusted odds ratio [OR] 0.56, 95% confidence interval [CI] 0.33–0.96). Lobular histology (adjusted OR 2.86, 95% CI 1.68–4.87), large tumor size (per millimeter increase, adjusted OR 1.05, 95% CI 1.03–1.07), high (>75%) mammographic density (adjusted OR 3.61, 95% CI 1.07–12.12), and the presence of microcalcifications (adjusted OR 4.45, 95% CI 2.69–7.37) and architectural distortions (adjusted OR 1.85, 95% CI 1.01–3.40) were independently associated with positive resection margins after BCS.

Conclusions. Preoperative MRI was associated with lower risk of positive resection margins in patients with invasive breast cancer eligible for BCS using multivariable analysis. Furthermore, specific mammographic characteristics and tumor characteristics were independently associated with positive resection margins after BCS.

Since the 1980s, breast-conserving surgery (BCS) has gradually replaced mastectomy as the standard treatment for early breast cancer.¹ BCS requires complete removal of the tumor, as positive resection margins have shown to be associated with an increased risk of local recurrence.²,³ In case of tumor-positive resection margins after BCS, a re-excision or mastectomy is performed. Reoperations are associated with physical and emotional burden for the patient, worse cosmetic results, and higher healthcare costs.⁴ Consequently, the re-excision rate is a national breast treatment quality indicator.⁵

© The Author(s) 2021
First Received: 23 December 2020
Accepted: 2 March 2021;
Published Online: 1 April 2021
J. J. J. Gommers, MSc
e-mail: Jessie.Gommers@radboudumc.nl

Annals of SURGICALONCOLOGY
OFFICIAL JOURNAL OF THE SOCIETY OF SURGICAL ONCOLOGY

https://doi.org/10.1245/s10434-021-09868-1

ORIGINAL ARTICLE – BREAST ONCOLOGY
Preoperative assessment of the extent of disease is crucial for surgical planning. To assess tumor size and location, clinical examination, mammography, and ultrasound are usually performed. However, measurement of tumor size by clinical examination and conventional imaging correlates poorly with histopathologic tumor size. Breast magnetic resonance imaging (MRI) has been shown to be more accurate than mammography or ultrasound to evaluate tumor size, multifocality, and the presence of contralateral breast cancer. As a result, breast MRI is increasingly being used in the preoperative evaluation of breast cancer.

Despite its increased use, the clinical value of preoperative breast MRI in patients with breast cancer undergoing BCS remains a topic of debate. The fact that breast MRI detects additional disease, not seen with conventional imaging, has created the impression that preoperative MRI improves surgical planning and the likelihood of complete tumor excision. However, meta-analyses have shown that preoperative MRI might lead to higher mastectomy rates without reducing re-excision rates after BCS. Since 2012, the use of preoperative MRI in The Netherlands has been advised in patients with invasive lobular breast cancer and in case of discrepancies between physical examination, mammography, and/or ultrasound.

Most studies on the potential benefits of preoperative MRI have included patients with clinically detected breast cancer. To our knowledge, data on the value of preoperative breast MRI in screen-detected cancer is lacking. Cancers detected in a screening program are usually non-palpable and smaller compared with clinically detected breast cancers. Exact localization of these screen-detected cancers is very important to be able to obtain clear resection margins. We used data from women who were recalled at biennial screening mammography in the south of The Netherlands to assess whether preoperative MRI reduces the risk of positive resection margins in patients with screen-detected breast cancer undergoing BCS. Second, we aimed to determine the factors associated with the risk of positive resection margins in patients with screen-detected breast cancer undergoing BCS.

METHODS

Study Population

We retrospectively analyzed all recalled women who received screening mammography at one of the four screening units in the south of The Netherlands between 1 January 2008 and 31 December 2017. Before being screened, women were offered the possibility to opt out of the use of their data for quality assurance and scientific purposes. Two women used this option and were therefore excluded from analysis. A total of 566,206 mammography screening examinations (61,635 initial screening examinations and 504,571 subsequent screening examinations) were included in this study. Figure 1 shows a flowchart of the study population. In total, 3737 women were diagnosed with a screen-detected breast cancer, of whom 3097 (82.9%) underwent BCS and were available for analysis on resection margins. According to the Dutch Central Committee on Research involving Human Subjects, ethical approval was not necessary. Our study was conducted in accordance with the Declaration of Helsinki.

Screening Procedure

In The Netherlands, women aged 50–75 years are invited to attend biennial screening mammography. Details of the nationwide screening program have been described elsewhere. In summary, screening mammograms were obtained by screening mammography radiographers and independently read by two certified screening radiologists. The screening radiologists classified the mammograms according to the Breast Imaging Reporting and Data System (BI-RADS). Women with normal (BI-RADS 1) or benign (BI-RADS 2) findings were invited to re-attend the biennial screening program (except for women who were in the last screening round). Women with mammographic abnormalities (BI-RADS 0, incomplete; 4, suspicious of malignancy; 5, highly suggestive of malignancy) were recalled for additional work-up at a hospital. BI-RADS 3 category is not used in the screening program as short-term follow-up is not available within our screening program. In case of a discordant reading between two screening radiologists (before 2015), one classifying the mammogram as BI-RADS 1 or 2 (no recall) and the other as BI-RADS 0, 4 or 5 (recall), the woman was recalled without a consensus meeting. From 2015 on, discordant readings were read by a third radiologist. The mammographic abnormalities of women who were recalled were categorized into one of the following categories: suspicious mass, suspicious microcalcifications, suspicious mass with microcalcifications, architectural distortion, asymmetry, or other suspicious abnormality. Breast density was classified according to BI-RADS.

Diagnostic Work-Up After Recall

A total of thirty hospitals were involved in the diagnostic work-up. At the hospitals, women underwent breast mammography, as well as physical examination. The clinical radiologist classified the mammogram according to the BI-RADS score. Bi-RADS 4 or 5 lesions were routinely biopsied and BI-RADS 3 lesions were either
biopsied or followed-up, as decided by the multidisci-
plinary breast team. Women with BI-RADS 1 or 2 lesions
were referred back to the screening program. Which tests
to use for the diagnostic work-up was at the discretion of
the breast radiologist and could include mammography,
breast tomosynthesis and/or ultrasound in combination
with tissue sampling of suspicious lesions, according to
Dutch and European guidelines. Furthermore, patients
could be discussed in multidisciplinary breast team meet-
ings, in which the necessity to perform breast MRI was
discussed, while considering the Dutch guidelines. Indi-
cations for preoperative MRI included dense breast tissue
as well as invasive lobular breast cancer, and breast MRIs
were performed to improve delineation of tumor size, to
detect ipsilateral (multifocal or multicentric) disease, to
exclude or confirm contralateral disease, and to help the
surgeon decide for BCS or mastectomy. Breast MRIs were
performed in different hospitals, using 1.5T or 3.0T MRI
machines from different vendors. In each hospital, dynamic
contrast-enhanced MRI was performed according to local
protocol, adhering to the quality criteria suggested by the
European Society of Breast Imaging (EUSOBI).

**Follow-Up of Recalled Women**

For all recalled women, radiology, biopsy, and surgery
reports were obtained and collected in Microsoft Excel
(Microsoft Corporation, Redmond, WA, USA). If a woman
was recalled for more than one lesion in a breast or for
bilateral lesions during the same screening round, the
lesion with the highest suspicion at mammography was
considered as the index lesion for recall.

Breast cancers were divided into ductal carcinoma
in situ (DCIS) and invasive cancers. Lobular carcinoma
in situ (LCIS) was classified as a lesion not needing
treatment, except pleomorphic LCIS, which was treated as
DCIS. Cancers were classified according to the Union for
International Cancer Control (UICC) TNM classification.
Until 2009, the UICC 6th edition was used, and from
2010 until 2016 and from 2017 onwards, the UICC 7th and
8th editions were used, respectively. Lymph nodes
were considered negative (N−) if they contained no tumor
or only isolated cells (≤0.2 mm), and were classified as
positive (N+) if they contained micrometastases
(>0.2–2 mm) or macrometastases (>2 mm). If ≥10% of
the cancer cells showed nuclear staining, estrogen and
progesterone status were considered positive. Human
epidermal growth factor receptor 2 (HER2) status was

![Breast cancer screening examinations and subsequent outcomes, from 2008 to 2017. DCIS ductal carcinoma in situ](image-url)
classified as positive in cases of HER2 immunohistochemistry (IHC) 3+ or HER2 IHC 2+ and amplified within in situ hybridization.\textsuperscript{14} Surgical margin status was registered as negative, focally positive ($\leq 4$ mm involved margin), or more than focally positive (>4 mm involved margin), according to the Dutch guideline for breast cancer.\textsuperscript{14} A more than focally involved margin was an indication for re-excision or mastectomy. In this study, specimens with more than focally involved margins were considered as tumor-positive margins and specimens with focally positive margins were considered as tumor-negative margins.

**Statistical Analysis**

Breast cancer patients who underwent BCS as primary treatment were eligible for inclusion. The study population was divided into a no MRI and an MRI group according to the preoperative use of breast MRI. Differences in patient and tumor characteristics between the two groups were tested using the Mann–Whitney U test for continuous variables and the Chi-square test for categorical variables. Univariable and multivariable binary logistic regression analyses were performed to determine the association between preoperative MRI and the presence of positive resection margins ($>4$ mm involved margin) after BCS. The multivariable method was performed by the enter method and included the variable preoperative MRI, as well as all variables that were associated with positive resection margins in univariable analysis (p-value <0.10). Missing values on covariates were imputed using multiple imputation (MI). If missing values showed a monotone pattern, the monotone MI method was used, but if the missing pattern was not monotone, the fully conditional specification was used.

Statistical analyses were performed using IBM SPSS Statistics version 25.0 (IBM SPSS Statistics for Windows, IBM Corporation, Armonk, NY, USA). Statistical tests were two-sided and p-values <0.05 were regarded as statistically significant.

**RESULTS**

**Patient and Tumor Characteristics**

Overall, 3737 women were diagnosed with a screen-detected breast cancer, of whom 3097 (82.9%) underwent BCS, 588 (15.7%) underwent mastectomy, and 52 (1.4%) underwent no surgery or their surgery was unknown. The percentage of women undergoing preoperative breast MRI was 15.8% in the BCS group and 46.4% in the mastectomy group.

A total of 3097 patients underwent BCS and were thus eligible for inclusion. Invasive cancer was diagnosed in 2483 patients, of whom 454 (18.3%) had received preoperative MRI. Pure DCIS was diagnosed in 614 women, of whom 35 (5.7%) had received preoperative MRI. Given the small number of women with DCIS who underwent preoperative MRI, we limited our analyses to women with invasive breast cancer.

Patient and tumor characteristics for women with invasive breast cancer are summarized in Table 1. Compared with women without preoperative MRI, women with preoperative MRI were generally younger ($p < 0.001$) and were found to have denser breasts ($p < 0.001$). Women with preoperative MRI had a higher proportion of masses with microcalcifications and architectural distortions on screening mammography, when compared with women without preoperative MRI ($p < 0.001$). Tumor histology also differed between women with and without preoperative MRI, with a higher proportion of invasive lobular cancers and less invasive ductal cancers among women who underwent preoperative MRI ($p < 0.001$). Furthermore, the tumors of women with preoperative MRI were generally larger ($p < 0.001$), more often lymph node-positive ($p < 0.001$), more frequently classified as Bloom and Richardson grade II ($p < 0.001$), and more often HER2 receptor-positive ($p = 0.017$) compared with the tumors of women without preoperative MRI.

**Surgical Resection Margins**

Overall, 123 (5.0%) women with invasive breast cancer had positive resection margins (more than focally involved margins). In absolute percentages, 6.6% (30/454) of the women with invasive breast cancer who underwent preoperative MRI had positive margins, compared with 4.6% (93/2029) in those who did not have preoperative MRI. In univariable analysis, preoperative MRI was not significantly associated with positive resection margins (odds ratio [OR] 1.47, 95% confidence interval [CI] 0.96–2.25) [Table 2]. However, after adjustment for possible confounders, the use of preoperative MRI was associated with a lower risk of positive resection margins, with an OR of 0.56 (95% CI 0.33–0.96). Confounders included breast density, mammographic abnormalities, tumor size, tumor histology, and lymph node status.

Irrespective of breast MRI use, the risk of having positive resection margins was higher in the presence of microcalcifications or architectural distortions compared with masses (OR 4.45, 95% CI 2.69–7.37, and OR 1.85, 95% CI 1.01–3.40, respectively). Furthermore, the risk of having positive resection margins was higher in breasts with a mammographic density of more than 75% compared with women with a breast density ≤25% (OR 3.61, 95% CI
|                              | Total \[N = 2483\] | Preoperative MRI \[n = 454\] | No preoperative MRI \[n = 2029\] | \(p\)-value   |
|------------------------------|------------------|-------------------------------|-------------------------------|----------------|
| Age, years                   |                  |                               |                               | \(<0.001^{a,a}\) |
| <60                          | 868 (35.0)       | 205 (45.2)                    | 663 (32.7)                    |                |
| 60–70                        | 1176 (47.4)      | 199 (43.8)                    | 977 (48.2)                    |                |
| >70                          | 439 (17.7)       | 50 (11.0)                     | 389 (19.2)                    |                |
| Breast density at screening mammogram, % |                  |                               |                               | \(<0.001^{a,a}\) |
| 0–25                         | 690 (34.6)       | 73 (21.1)                     | 617 (37.4)                    |                |
| 25–50                        | 925 (46.4)       | 161 (46.5)                    | 764 (46.4)                    |                |
| 50–75                        | 347 (17.4)       | 99 (28.6)                     | 248 (15.0)                    |                |
| 75–100                       | 32 (1.6)         | 13 (3.8)                      | 19 (1.2)                      |                |
| Unknown                      | 489              | 108                           | 381                           |                |
| Mammographic abnormality     |                  |                               |                               | \(<0.001^{a,a}\) |
| Mass                         | 1810 (72.9)      | 288 (63.4)                    | 1522 (75.0)                   |                |
| Microcalcifications          | 210 (8.5)        | 38 (8.4)                      | 172 (8.5)                     |                |
| Mass with microcalcifications| 199 (8.0)        | 51 (11.2)                     | 148 (7.3)                     |                |
| Symmetry                     | 78 (3.1)         | 17 (3.7)                      | 61 (3.0)                      |                |
| Architectural distortion     | 164 (6.6)        | 51 (11.2)                     | 113 (5.6)                     |                |
| Other                        | 22 (0.9)         | 9 (2.0)                       | 13 (0.6)                      |                |
| Tumor histology              |                  |                               |                               | \(<0.001^{a,a}\) |
| Ductal                       | 1992 (80.2)      | 260 (57.3)                    | 1732 (85.4)                   |                |
| Lobular                      | 266 (10.7)       | 163 (35.9)                    | 103 (5.1)                     |                |
| Mixed ductal-lobular         | 78 (3.1)         | 19 (4.2)                      | 59 (2.9)                      |                |
| Other                        | 147 (5.9)        | 12 (2.6)                      | 135 (6.7)                     |                |
| Tumor size, mm\(^c\)         | 12 (8–17)        | 16 (12–24)                    | 11 (8–15)                     | \(<0.001^{b,a}\) |
| Lymph node status            |                  |                               |                               | \(<0.001^{a,a}\) |
| N+                           | 463 (19.1)       | 137 (30.5)                    | 326 (16.5)                    |                |
| N–                           | 1967 (80.9)      | 312 (69.5)                    | 1655 (83.5)                   |                |
| Unknown                      | 53               | 5                             | 48                            |                |
| Bloom and Richardson grade   |                  |                               |                               | \(<0.001^{a,a}\) |
| I                            | 1145 (46.4)      | 165 (36.4)                    | 980 (48.6)                    |                |
| II                           | 1060 (42.9)      | 243 (53.6)                    | 817 (40.5)                    |                |
| III                          | 264 (10.7)       | 45 (9.9)                      | 219 (10.9)                    |                |
| Unknown                      | 14               | 1                             | 13                            |                |
| Estrogen receptor status     |                  |                               |                               | 0.715\(^a\) |
| Positive                     | 2256 (91.2)      | 412 (90.7)                    | 1844 (91.3)                   |                |
| Negative                     | 218 (8.8)        | 42 (9.3)                      | 176 (8.7)                     |                |
| Unknown                      | 9                | 0                             | 9                             |                |
| Progesterone receptor status |                  |                               |                               | 0.139\(^a\) |
| Positive                     | 1790 (72.6)      | 316 (69.8)                    | 1474 (73.2)                   |                |
| Negative                     | 677 (27.4)       | 137 (30.2)                    | 540 (26.8)                    |                |
| Unknown                      | 16               | 1                             | 15                            |                |
| HER2 receptor status         |                  |                               |                               | 0.017\(^{a,*}\) |
| Positive                     | 208 (8.4)        | 51 (11.2)                     | 157 (7.8)                     |                |
| Negative                     | 2260 (91.6)      | 403 (88.8)                    | 1857 (92.2)                   |                |
| Unknown                      | 15               | 0                             | 15                            |                |
| Resection margin             |                  |                               |                               | 0.167\(^a\) |
| More than focally positive   | 123 (5.0)        | 30 (6.6)                      | 93 (4.6)                      |                |
| Focally positive             | 216 (8.7)        | 42 (9.3)                      | 174 (8.6)                     |                |
The likelihood of having positive resection margins was almost three times higher in patients with invasive lobular cancer when compared with patients with invasive ductal cancer (OR 2.86, 95% CI 1.68–4.87) and the risk of having positive resection margins increased per millimeter increase in tumor size (OR 1.05, 95% CI 1.03–1.07).

**DISCUSSION**

Multivariable analysis showed that selective use of preoperative MRI in women with invasive breast cancer undergoing BCS after recall at screening mammography was associated with a lower risk of positive resection margins (more than focally \([>4\text{~mm}]\) involved margins). Furthermore, we found that the presence of microcalcifications and architectural distortions, high (\(>75\%\)) mammographic breast density, lobular histology, and increasing tumor size were independently associated with positive resection margins after BCS.

Surgical resection with tumor-free margins is one of the main challenges in BCS. According to the American Society for Radiation Oncology Consensus Guideline, no ink on tumor is the standard for an adequate margin in invasive breast cancer.\(^{26}\) However, in The Netherlands, reexcision or mastectomy is only recommended for more than focally \([>4\text{~mm}]\) involved margins. Furthermore, we found that the presence of microcalcifications and architectural distortions, high (\(>75\%\)) mammographic breast density, lobular histology, and increasing tumor size were independently associated with positive resection margins after BCS.

Data are expressed as \(n\) (%) unless otherwise specified. Missing cases are not included in the percentages.

**TABLE 1**

|                  | Total \([N = 2483]\) | Preoperative MRI \([n = 454]\) | No preoperative MRI \([n = 2029]\) | \(p\)-value |
|------------------|----------------------|-------------------------------|-----------------------------------|------------|
| Negative         | 2144 (86.3)          | 382 (84.1)                    | 1762 (86.8)                       |            |

**HER2** human epidermal growth factor receptor 2, **MRI** magnetic resonance imaging, **N+** lymph node-positive, **N-** lymph node-negative (including isolated tumor cells)

Denotes statistical significance at \(p < 0.05\)

\(^{*}\)Chi-square test; missing values were not included

\(^{b}\)Mann–Whitney U test; missing values were not included

\(^{c}\)Data are median (25th and 75th percentiles). Tumor size was not known in two patients in the MRI group and one patient in the no MRI group.

1.07–12.12). The likelihood of having positive resection margins was higher in the MRI group than the no MRI group, although not significant. However, tumor characteristics of women who received preoperative breast MRI were less favorable than those without preoperative MRI. For example, women undergoing MRI had larger tumors and were more likely to have invasive lobular cancer, which were predefined criteria to perform MRI, as stated in the national guidelines. It is known that these factors increase the risk of positive resection margins,\(^{1,29–31}\) and this could have been the reason for performing MRI and thus be a source of selection bias, masking the real effect of preoperative MRI upon margin status. After adjustment for these and other potential confounders in a multivariable analysis, the use of preoperative breast MRI was associated with a lower risk of more than focally positive resection margins (adjusted OR 0.56, 95% CI 0.33–0.96; \(p = 0.033\)), indicating the added value of preoperative MRI in this screen-detected population.

To our knowledge, only one previous study investigated the association between preoperative MRI and margin involvement in women recalled at screening mammography.\(^{1}\) This study similarly concluded that preoperative MRI in patients with invasive breast cancer was associated with a lower risk of positive resection margins after BCS (adjusted OR 0.42; \(p = 0.015\)).\(^{1}\) However, Nederend et al.\(^{1}\) included women screened between 1997 and 2011, when the risk of positive resection margins was considerably higher compared with our study period (11.6% vs. 5%). Other studies that investigated the association between preoperative MRI and margin involvement mainly focused on symptomatic breast cancer patients and provided conflicting results.\(^{4,5,31–36}\) In line with the present findings, some studies showed that breast MRI use was associated with a reduced number of positive resection margins in patients with invasive breast cancer eligible for BCS.\(^{1,4,31,34}\) Lobbes et al.\(^{31}\) showed that the use of preoperative MRI was significantly associated with a lower risk of positive resection margins in patients with invasive breast cancer eligible for BCS.
TABLE 2 Univariable and multivariable logistic regression analyses of associations with positive resection margins (more than focally [>4 mm] involved margins) in women with invasive breast cancer diagnosed after recall at screening mammography

|                                | OR, univariable analysis (95% CI) | p-value | OR, multivariable analysis* (95% CI) | p-value |
|--------------------------------|-----------------------------------|---------|-------------------------------------|---------|
| Preoperative MRI               |                                   |         |                                     |         |
| No                             | 1.0 (ref)                          | NA      | 1.0 (ref)                            | NA      |
| Yes                            | 1.47 (0.96–2.25)                   | 0.074   | 0.56 (0.33–0.96)*                    | 0.033*  |
| Age, per year increase         | 1.01 (0.98–1.03)                   | 0.657   | NA                                  | NA      |
| Breast density at screening mammogram, % |                       |         |                                     |         |
| 0–25                          | 1.0 (ref)                          | NA      | 1.0 (ref)                            | NA      |
| 25–50                         | 1.40 (0.89–2.23)                   | 0.149   | 1.28 (0.79–2.08)                     | 0.321   |
| 50–75                         | 1.76 (0.98–3.16)                   | 0.057   | 1.31 (0.68–2.53)                     | 0.421   |
| 75–100                        | 6.77 (2.71–16.90)*                | <0.001* | 3.61 (1.07–12.12)*                   | 0.039*  |
| Mammographic abnormality       |                                   |         |                                     |         |
| Mass                           | 1.0 (ref)                          | NA      | 1.0 (ref)                            | NA      |
| Microcalcifications            | 4.07 (2.55–6.49)*                 | <0.001* | 4.45 (2.69–7.37)*                    | <0.001* |
| Mass with microcalcifications  | 1.25 (0.61–2.55)                   | 0.537   | 1.33 (0.64–2.75)                     | 0.446   |
| Asymmetry                      | 0.34 (0.05–2.51)                   | 0.292   | 0.13 (0.01–1.43)                     | 0.095   |
| Architectural distortion       | 3.06 (1.75–5.35)*                 | <0.001* | 1.85 (1.01–3.40)*                    | 0.047*  |
| Other                          | 2.64 (0.61–11.54)                  | 0.196   | 2.22 (0.40–12.33)                    | 0.360   |
| Tumor size, per mm increase    | 1.05 (1.04–1.07)*                 | <0.001* | 1.05 (1.03–1.07)*                    | <0.001* |
| Tumor histology                |                                   |         |                                     |         |
| Ductal                         | 1.0 (ref)                          | NA      | 1.0 (ref)                            | NA      |
| Lobular                        | 2.74 (1.75–4.30)*                 | <0.001* | 2.86 (1.68–4.87)*                    | <0.001* |
| Mixed ductal-lobular           | 3.04 (1.47–6.30)*                 | 0.003*  | 2.38 (1.07–5.31)*                    | 0.034*  |
| Other                          | 0.65 (0.24–1.80)                   | 0.409   | 0.74 (0.26–2.09)                     | 0.571   |
| Lymph node status              |                                   |         |                                     |         |
| N−                             | 1.0 (ref)                          | NA      | 1.0 (ref)                            | NA      |
| N+                             | 1.96 (1.31–2.95)*                 | 0.001*  | 1.53 (0.98–2.40)                     | 0.060   |
| Bloom and Richardson grade     |                                   |         |                                     |         |
| I                              | 1.0 (ref)                          | NA      | NA                                  | NA      |
| II                             | 1.14 (0.77–1.68)                   | 0.517   | NA                                  | NA      |
| III                            | 1.15 (0.63–2.10)                   | 0.657   | NA                                  | NA      |
| Estrogen receptor status       |                                   |         |                                     |         |
| Positive                       | 1.0 (ref)                          | NA      | NA                                  | NA      |
| Negative                       | 0.91 (0.47–1.77)                   | 0.784   | NA                                  | NA      |
| Progesterone receptor status   |                                   |         |                                     |         |
| Positive                       | 1.0 (ref)                          | NA      | NA                                  | NA      |
| Negative                       | 0.90 (0.60–1.34)                   | 0.606   | NA                                  | NA      |
| HER2 receptor status           |                                   |         |                                     |         |
| Positive                       | 1.0 (ref)                          | NA      | NA                                  | NA      |
| Negative                       | 0.65 (0.37–1.13)                   | 0.125   | NA                                  | NA      |

CI confidence interval, HER2 human epidermal growth factor receptor 2, MRI magnetic resonance imaging, NA not applicable, N+ lymph node-positive, N− lymph node-negative, OR odds ratio

Positive resection margins include specimens with more than focally involved (>4 mm) margins. Specimens with focally involved and negative margins were considered as tumor-negative margins.

*Denotes statistical significance at p < 0.05. Missing values were imputed by multiple imputation.

*aAdjustment for variables associated with positive resection margins with p < 0.100 in univariable analysis.
breast cancer (adjusted OR 0.84; \( p = 0.015 \)), which was mainly attributable to the effect observed in patients with invasive lobular carcinoma (adjusted OR 0.59; \( p < 0.001 \)).

Several other studies showed little or no effect,\(^{3,33,35,36}\) or even an unfavorable effect,\(^{32}\) of preoperative MRI on margin status. A plausible explanation of why additional information regarding MRI is not always translated into improved margin status is that MRI is usually performed in the prone position whereas surgery is performed in the supine position. Gombos et al.\(^{37}\) showed considerable change of the breast contour and tumor position between MRI performed in the supine and prone positions. They suggested that intraoperative supine breast MRI, in conjunction with standard prone breast MRI, may help in understanding the actual position of the breast tumors and thereby improve margin status. Moreover, the impact of MRI may depend on the experience of radiologists and surgeons, as well as on the multidisciplinary team communication. Differentiation as breast radiologist and surgeon should optimize mutual understanding and correct surgical planning.

It is often argued that preoperative MRI increases the likelihood of undergoing mastectomy. We observed that the fraction of patients who underwent preoperative MRI was larger in women who underwent mastectomy compared with women who underwent BCS. This is not unexpected since our study shows that the use of breast MRI increases with less favorable tumor characteristics and tumor size. Commonly, breast MRI is used to confirm the need for mastectomy or to enable the choice between primary surgical therapy or primary systemic therapy. However, as breast MRI in general shows more cancer than conventional imaging techniques, it is likely that the use of MRI in a number of patients has led to the performance of a mastectomy that would have been avoided without this evaluation. However, the low percentage of mastectomies (15.7%) shows that in women with screen-detected breast cancer this does not seem to be a major problem.

Irrespective of the use of preoperative MRI, the present study found that the presence of microcalcifications and architectural distortions, a high (>75%) mammographic breast density, lobular histology, and increasing tumor size were independently associated with positive resection margins. Similar to our findings, previous studies also reported lobular histology and large tumor size as risk factors for positive resection margins.\(^{1,29–31}\) Shin et al. also reported that a mammographic breast density of more than 75% was significantly associated with positive resection margins.\(^{38}\) High mammographic density makes localization and determination of the size of a tumor difficult\(^{39}\) and may thus explain why women with higher breast density are at higher risk of positive resection margins. The clinical impact of this result should be put into perspective, as <2% of the women in our study had a breast density of more than 75%. The higher risk for margin involvement in women with microcalcifications on mammography, observed in the present study, is also in line with previous studies.\(^{1,29,38,40}\) Microcalcifications are known to be associated with the presence of an extensive in situ component, the size of which is often underestimated by conventional imaging.\(^{1,44}\) We assume that microcalcifications on mammography indicate the presence of invasive cancer with DCIS, which could be considered an indication to perform MRI, as an extensive in situ component is known to be associated with involved resection margins after BCS.\(^{1,30}\)

Architectural distortions on mammography were also previously found to be predictive for positive resection margins,\(^{42–44}\) which may be due to the fact that tumors characterized as architectural distortions can grow in a particularly infiltrative pattern, making it more difficult to determine resection margins.

The major strength of the present study was the large study population of women with screen-detected breast cancer. Our study is one of the few studies that evaluated the impact of preoperative MRI in screen-detected cancers, as most studies focused on clinically detected cancers. Moreover, our data provided insight into many variables, including imaging features, tumor characteristics, and surgical outcomes. However, extrapolation of our findings to other screening programs should be interpreted with caution as this study was performed in a Dutch screening population for which the design and work-up strategies differ from other countries. A second limitation is the non-randomized design of our study, which makes it difficult to exclude unrecognized differences between women who underwent preoperative MRI and those who did not.

Finally, our sample size was too small for subgroup analyses on resection margins, such as for invasive ductal and lobular carcinomas. Furthermore, even though we included almost 2500 recalled women with invasive carcinoma, only 123 women (30 in the MRI group and 93 in no MRI group) had positive resection margins (>4 mm involved margins). This reduced the statistical power of our analyses.

**CONCLUSION**

We found that selective use of preoperative MRI was associated with improved margin status after BCS in patients with screen-detected invasive breast cancer using multivariable analysis. Moreover, the presence of microcalcifications and architectural distortions, high (>75%) mammographic breast density, lobular histology, and increasing tumor size were independently associated with positive resection margins (>4 mm involved margins) after BCS. As most of these factors can be assessed
Impact of Preoperative Breast MRI

preoperatively, they may improve surgical planning and reduce the risk of positive resection margins after BCS. Regarding our results, it can be argued to perform preoperative MRI in the high-risk settings described: microcalcifications, architectural distortions, high (>75%) breast density, and large tumors. Lobular histology is already being considered as an indication to perform preoperative MRI.

ACKNOWLEDGMENTS The authors acknowledge the Dutch National Breast Cancer Screening Program for providing data on mammography.

AUTHOR CONTRIBUTIONS JJJG edited the dataset, performed the statistical analysis, and wrote the manuscript. LEMD designed the study, performed data collection, and maintains the database on screening outcome in the south of The Netherlands. ACV helped perform data analyses. All authors were involved in the interpretation of data and reviewed the manuscript.

FUNDING No sources of funding were received for this study.

DISCLOSURE Ritse Mann has received research grants from Siemens Healthineers and Bayer Healthcare. Jessie J.I. Gommers, Lucien E.M. Duijm, Peter Bult, Luc J.A. Strobbe, Toon P. Kuipers, Marianne J.H. Hooijen, and Adrie C. Voogd have no conflicts of interest to declare.

OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

REFERENCES

1. Nederend J, Duijm LE, Louwman MW, Roumen RM, Jansen FH, Voogd AC. Trends in surgery for screen-detected and interval breast cancers in a national screening programme. Br J Surg. 2014;101(8):949–58. https://doi.org/10.1002/bjs.9530.
2. Houssami N, Macaskill P, Marinovich ML, Morrow M. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving surgery: a meta-analysis. Ann Surg Oncol. 2014;21(3):717–30. https://doi.org/10.1245/s10434-014-3480-5.
3. Bhatti AB, Khan A, Muzaffar N, Siddiqui N, Syed A, Shah M, et al. Safe negative margin width in breast conservative therapy: results from a population with a high percentage of negative prognostic factors. World J Surg. 2014;38(11):2863–70. https://doi.org/10.1007/s00268-014-2651-7.
4. Obdeijn IM, Tīlans-Līnshorst MM, Sprok S, van Deurzen CH, de Monye C, Hunink MG, et al. Preoperative breast MRI can reduce the rate of tumor-positive resection margins and reoperations in patients undergoing breast-conserving surgery. AJR Am J Roentgenol. 2013;200(2):304–10. https://doi.org/10.2214/ajr.1.29185.
5. Vos EL, Voogd AC, Verhoef C, Siesling S, Obdeijn IM, Koppert LB. Benefits of preoperative MRI in breast cancer surgery studied in a large population-based cancer registry. Br J Surg. 2015;102(13):1649–57. https://doi.org/10.1002/bjs.9947.
6. Berg WA, Gutierrez L, NessArver MS, Carter WB, Bhargavan M, Lewis RS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830–49. https://doi.org/10.1148/radiol.2333031484.
7. Mann RM, Balleyguier C, Balzter PA, Bick U, Colin C, Cornford E, et al. Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol. 2015;25(12):3669–78. https://doi.org/10.1007/s00330-015-3807-z.
8. Van Goethem M, Tjalma W, Scheflout K, Verslegers I, Biltjes I, Parizel P. Magnetic resonance imaging in breast cancer. Eur J Surg Oncol. 2006;32(9):901–10. https://doi.org/10.1016/j.ejso.2006.06.009.
9. Gruber IV, Rueckert M, Kagan KO, Staebler A, Siegmann KC, Hartkopf A, et al. Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer. BMC Cancer. 2013;13:328. https://doi.org/10.1186/1471-2407-13-328.
10. Killelea BK, Long JB, Chagpar AB, Ma X, Soulos PR, Ross JS, et al. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treat. 2013;141(1):155–63. https://doi.org/10.1007/s10549-013-2656-1.
11. Tartar M, Comstock CE, Kipper MS. Breast cancer imaging: a multidisciplinary, multimodality approach. London: Mosby; 2008. p. 632.
12. Houssami N, Turner RM, Morrow M. Meta-analysis of pre-operative magnetic resonance imaging (MRI) and surgical treatment for breast cancer. Breast Cancer Res Treat. 2017;165(2):273–83. https://doi.org/10.1007/s10549-017-4324-3.
13. Fancellu A, Turner RM, Dixon JM, Pinna A, Cottu P, Houssami N. Meta-analysis of the effect of preoperative breast MRI on the surgical management of ductal carcinoma in situ. Br J Surg. 2015;102(8):883–93. https://doi.org/10.1002/bjs.9797.
14. Richtlijn borsiakanker. National Breast Cancer Organization of the Netherlands (NABON). https://www.oncoline.nl/ Accessed 20 Feb 2020.
15. Your research: Is it subject to the WMO or not? Central Committee on Research Involving Human Subjects. https://english.ccmo.nl/investigators/legal-framework-for-medical-scientific-research/your-research-is-it-subject-to-the-wmo-or-not. Accessed April 2020.
16. Fracheboud J, de Koning HJ, Boer R, Groenenwoud JH, de Koning HJ, Boer R, Groenenwoud JH, et al. Preoperative breast MRI can reduce the rate of tumour-positive resection margins and reoperations in patients undergoing breast-conserving surgery. AJR Am J Roentgenol. 2013;200(2):304–10. https://doi.org/10.2214/ajr.1.29185.
20. Sickles EA, D’Orsi CJ, Bassett LW, et al. ACR BI-RADS® Mammo-
graphy. In: ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. 5th edn. American College of Radiology; 2013.

21. Amendoeira I, Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, et al. European guidelines for quality assurance in breast cancer screening and diagnosis. Brussels: European Commission; 2013.

22. Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. Eur Radiol. 2008;18(7):1307–18. https://doi.org/10.1007/s00330-008-0863-7.

23. Wittekind C, Sobin L. TNM classification of malignant tumours. 6th edn. New York: Wiley; 2002.

24. Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th edn. New York: Wiley; 2011.

25. Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th edn. New York: Wiley; 2017.

26. Moran MS, Schnitt SJ, Giuliano AE, Harris JR, Khan SA, Horton J, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer. Int J Radiat Oncol Biol Phys. 2014;88(3):553–64. https://doi.org/10.1016/j.ijrobp.2013.11.012.

27. Vos EL, Siesling S, Baaijens MHA, Verhoef C, Jager A, Voogd AC, et al. Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival. Breast Cancer Res Treat. 2017;164(1):157–67. https://doi.org/10.1007/s10549-016-4232-6.

28. van Bommel AC, Sponk PE, Vrancken Peeters MT, Jager A, Lobbes M, Maduro JH, et al. Clinical auditing as an instrument for quality improvement in breast cancer care in the Netherlands: the national NABON Breast Cancer Audit. J Surg Oncol. 2017;115(3):243–9. https://doi.org/10.1002/jso.24516.

29. Kurniawan ED, Wong MH, Windle I, Rose A, Mou A, Buchanan M, et al. Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol. 2008;15(9):2542–9. https://doi.org/10.1245/s10434-008-0054-4.

30. van Deurzen CHM. Predictors of surgical margin following breast-conserving surgery: a large population-based cohort study. Ann Surg Oncol. 2016;23(Suppl 5):627–33. https://doi.org/10.1245/s10434-016-5532-5.

31. Lobbes MBI, Vriens IJH, van Bommel ACM, Nieuwenhuijzen GAP, Smidt ML, Boersma LJ, et al. Breast MRI increases the number of mastectomies for ductal cancers, but decreases them for lobular cancers. Breast Cancer Res Treat. 2017;162(2):353–64. https://doi.org/10.1007/s10549-017-4117-8.

32. Peters NH, van Esser S, van den Bosch MA, Storm RK, Plaisier PW, van Dalen T, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET—randomised controlled trial. Eur J Cancer. 2011;47(6):879–86. https://doi.org/10.1016/j.ejca.2010.11.035.

33. Turnbull L, Brown S, Harvey I, Olivier C, Drew P, Napp V, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: a randomised controlled trial. Lancet. 2010;375(9714):563–71. https://doi.org/10.1016/S0140-6736(09)62070-5.

34. Lai HW, Chen CJ, Lin YJ, Chen SL, Wu HK, Wu YT, et al. Does breast magnetic resonance imaging combined with conventional imaging modalities decrease the rates of surgical margin involvement and reoperation? A case-control comparative analysis. Medicine (Baltimore). 2016;95(22):e3810. https://doi.org/10.1097/md.0000000000003810.

35. Pengel KE, Loo CE, Teertstra HJ, Muller SH, Wesseling J, Peterse JL, et al. The impact of preoperative MRI on breast-conserving surgery of invasive cancer: a comparative cohort study. Breast Cancer Res Treat. 2009;116(1):161–9. https://doi.org/10.1007/s10549-008-0182-3.

36. Bleicher RJ, Ciocca RM, Egleston BL, Sesa L, Evers K, Sigurdson ER, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg. 2009;209(2):180–7; quiz 294-5. https://doi.org/10.1016/j.jamcollsurg.2009.04.010.

37. Gombok EC, Jayender J, Richman DM, Caragacianu DL, Mallory MA, Jolesz FA, et al. Intraoperative supine breast MR imaging to quantify tumor deformation and detection of residual breast cancer: preliminary results. Radiology. 2016;281(3):720–9. https://doi.org/10.1148/radiol.2016151472.

38. Shin HC, Han W, Moon HG, Cho N, Moon WK, Park IA, et al. Nomogram for predicting positive resection margins after breast-conserving surgery. Breast Cancer Res Treat. 2012;134(3):1115–23. https://doi.org/10.1007/s10549-012-2124-3.

39. Bani MR, Lux MP, Heusinger K, Wendtland R, et al. Factors correlating with reexcision after breast-conserving therapy. Eur J Surg Oncol. 2009;35(1):32–7. https://doi.org/10.1016/j.ejso.2008.04.008.

40. Saadai P, Moezzi M, Menes T. Preoperative and intraoperative predictors of positive margins after breast-conserving surgery: a retrospective review. Breast. 2011;18(3):221–5. https://doi.org/10.1016/j.breast.2011.02-062-9.

41. Eichler C, Abrar S, Puppe J, Arndt M, Ohlinger R, Hahn M, et al. Detection of ductal carcinoma in situ by ultrasound and mammography: size-dependent inaccuracy. Anticancer Res. 2017;37(9):5065–70. https://doi.org/10.21873/anticancerres.11923.

42. Gajdos C, Tartter PI, Bleiweiss IJ, Hermann G, de Csepel J, Estabrook A, et al. Mammographic appearance of nonpalpable breast cancer reflects pathologic characteristics. Ann Surg. 2002;235(2):246–51. https://doi.org/10.1097/00000658-200202000-00013.

43. Moore MM, Borossa G, Imbrie JZ, Fechner RE, Harvey JA, Slingluff CL Jr, et al. Association of infiltrating lobular carcinoma with positive surgical margins after breast-conservation therapy. Ann Surg. 2000;231(6):877–82. https://doi.org/10.1097/00000658-200006000-00012.

44. Silberfein EJ, Hunt KK, Broglio K, Sessa L, Sigurdson ER, et al. Association of routine pretreatment magnetic resonance imaging with time to surgery, mastectomy rate, and margin status. J Am Coll Surg. 2009;209(2):180–7; quiz 294-5. https://doi.org/10.1016/j.jamcollsurg.2009.04.010.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.